



The 2nd International On-line Symposium “Chronic viral infections and cancer, openings for vaccines” December 16-17, 2021 www.techvac.org

Symposium Co-Chairs

- Dr Maria Isaguliantis, Riga Stradins University, Latvia; Karolinska Institutet, Sweden; National Center for Epidemiology and Microbiology named after N.F. Gamaleya, and Peoples' Friendship University of Russia, Moscow, Russia;
- Dr Franco Buonaguro, Molecular Biology and Viral Oncology, Department of Experimental Oncology, Istituto Nazionale Tumori Fond Pascale, Naples, Italy;

Program Committee

- Dr Birke Bartosch, INSERM Research Director, Cancer Research Center of Lyon, France;
- Dr Franco Buonaguro, Molecular Biology and Viral Oncology, Department of Experimental Oncology, Istituto Nazionale Tumori Fond Pascale, Naples, Italy;
- Dr Alexander Ivanov, Engelhardt Institute of Molecular Biology, Moscow, Russia;
- Dr Maria Isaguliantis, Riga Stradins University, Latvia; Karolinska Institutet, Sweden; National Center for Epidemiology and Microbiology named after N.F. Gamaleya, and Peoples' Friendship University of Russia, Moscow, Russia;
- Dr Ujjwal Neogi, Department of Medicine, Karolinska Institute, Stockholm, Sweden.

Organizing Committee

- Dr Maria Isaguliantis, Associate Professor of Immunology, Riga Stradins University, Latvia, Karolinska Institutet, Sweden, National Center for Epidemiology and Microbiology named after N.F. Gamaleya, and Peoples' Friendship University of Russia, Moscow, Russia maria.issagouliantis@rsu.lv;
- Dr Ivan Trotsenko, Peoples' Friendship University of Russia, Moscow, Russia;
- Dr Natalia Petrakova, National Center for Epidemiology and Microbiology named after N.F. Gamaleya, Moscow, Russia;
- Ms Darina Prososhina, Monomax Ltd, St Petersburg, Russia; techvac@onlinereg.ru

Managment:



Monomax Congress Service

Address: Sestroretskaya St., Bld 2, St. Petersburg, 197183 Russia

Tel: +7 (812) 335 2055

Fax: +7 (812) 335 2039

E-mail: feedback@monomax.org

Web site: <http://monomax.ru/en/>

Science field covered by Symposium

Approximately one out of eight human cancers has a viral etiology. Viral cancers present unique opportunities for prophylaxis, diagnosis, and therapy, as demonstrated by the success of HBV and HPV vaccines and HCV antivirals in decreasing the incidence of tumors that are caused by these viruses.

For other chronic viral infections and related cancers, problems still dominate over the progress. Prophylactic HPV vaccination does not cure already established infections, urgently requesting development of therapeutic HPV vaccines. Several are in pipeline, but still far from actual application for treatment of HPV-related cancers. Development of HCV vaccines is in progress, but is hampered by HCV variability and absence of longitudinal sterilizing anti-viral response. The success of antiretroviral therapy in controlling HIV-1 replication and immune reconstitution did not lead to significant reduction of HIV-1 associated cancers indicating alternative mechanisms of their development, not connected to immune suppression.

Symposium will unravel the progress in the studies of the molecular pathogenesis of chronic viral infections, cover common mechanisms of action of human oncogenic viruses, such as the activity of viral oncoproteins, induction of genomic instability, support of chronic inflammation, and modulation of tumor microenvironment. Special attention will be devoted to virus-induced alterations in the functions of immune system, induction of innate and adaptive immune responses including the relationship between metabolism and the immune response to viral infections, and immunometabolism on the cellular level. In-depth understanding of these processes would create new openings to the design of novel viral vaccines and immunotherapies.

Symposium program

Symposium held during two days by Zoom will be divided into 4 sessions and 8 sections:

SESSION 1. MOLECULAR PATHOGENESIS OF CHRONIC VIRAL INFECTIONS

Section 1.1 Chronic viral infections and oxidative stress

Section 1.2 Metabolic signatures of chronic viral infections

SESSION 2. CHRONIC VIRAL INFECTIONS AND CANCER

Section 2.1 Factors determining viral oncogenicity

Section 2.2 Chronic viral infections and genomic instability

Section 2.3 Viral infections and chronic inflammation

SESSION 3. POSTER PRESENTATIONS (5 min orals with poster viewing)

SESSION 4. IMMUNITY TO CHRONIC VIRAL INFECTIONS AND OPENINGS FOR VACCINE DEVELOPMENT

Section 4.1 Innate and adaptive immunity weak points

Section 4.2 Immunometabolism of chronic viral infections

Section 4.3 Approaches to counteract viral and cancer alterations in metabolism, and immunometabolism

Section 4.4 Approaches to counteract viral and cancer alterations in immunogenic performance

Each section will be opened by invited plenary lecture. Plenary lectures will be read by the renown experts in the field of virology, immunology and oncology, see www.techvac.org for the names and topics.

Preliminary interest to participate with presentations was already expressed by >100 researchers from France, Italy, Germany, Ireland, Sweden, Norway, Latvia, USA, South Africa, China, Japan, and Russia.

Publication of conference materials

Program committee will review all submitted abstracts, and select high quality submissions for oral and poster presentation on the Symposium. All accepted abstracts will be published in a special issue of "INFECTIOUS AGENTS AND CANCER", BMC journal (Springer Nature), Q2 in Infectious Diseases; IF Web of Science 2.7; IF Scopus 4.3 <https://infectagentscancer.biomedcentral.com/about> edited by Dr Maria Isaguliantis and Prof Franco Maria Buonaguro. Program committee will recommend a selection of abstracts for submission as full-length manuscripts to be published in the above journal issue if accepted. Manuscript corresponding to the best oral given by young carrier researcher selected by the Program Committee and successfully passing revision process will be published free of charge.

Partners

- International Society for Vaccines (ISV) <https://isv-online.org/>
- Riga Stradins University, Riga, Latvia www.rsu.lv
- Peoples' Friendship University of Russia, Moscow, Russia – RUDN <https://eng.rudn.ru/>
- National Center for Epidemiology and Microbiology named after NF Gamaleya, Moscow, Russia – NCEM www.gamaleya.org
- Papilloma Society (Moscow, Russia)

If your organization is interested in becoming a partner for this event, please, contact Organizing Committee to learn more on the potential partner inputs.

Participation of commercial companies

If company wishes to present research, it should register at least one participant and submit an abstract describing the contents of the planned presentation in English. Abstract should be formatted as described on the web. The abstract will be evaluated by program committee and has to be accepted for presentation along with other submitted abstracts. Abstracts containing information advertising the company will not be considered. Advertisement can only be made by actors registered as symposium sponsors (see below).

Sponsors

Symposium organizers welcome sponsor support, but are careful in accepting sponsor help, as sponsors shape the face of the event. Decision to accept sponsorship is made jointly by Organizing and Program Committees based on the letter of interest. Letter should describe the company offering sponsor support, what kind of products and services company offers, why it is interested to participate and offer help, and what are the expected outcomes/benefits. Decision on acceptance is made within a week after receiving the letter.

Sponsorship package equal to 1000 euro includes:

- Access to all sessions/sections and to conference materials;

- Access to recorded presentations or presentation files (if permitted by the authors);
- Presentation (10 min) at the opening or closing of the symposium*;
- Demonstration of sponsor company name and logotype on the screen between the sessions;
- Printing of sponsor company name and logotype in the special issue of "INFECTIOUS AGENTS AND CANCER" alongside with conference abstracts;
- Publication on Symposium website of sponsor name, logotype and advertising materials – up-to 1 page of text and presentation as a Power Point or pdf file. Sponsor information will be published on symposium website after the decision of acceptance. Sponsor presentations will be published after the symposium. Prior to publication, both files will be reviewed by Program and Organizing Committees.

** Submission of abstract is not required. It is sufficient to submit presentation title and speakers name(s) and affiliation. Oral will be included in the program with a remark "Sponsor presentation".*

Sponsors are prompted to pay directly after they receive the decision on sponsorship acceptance. If no payment is received by TECHVAC management by December 15, 2021, sponsor information will be removed from the web and from the program.

Beware that symposium can accept max five sponsorships due to limited time available for sponsor presentations.

Please, address offers of sponsor support to symposium manager Ms Darina Prososhina techvac@onlinereg.ru.